PapGene, Inc., a leader in the field of liquid biopsy and focused on the development of high-performance tests to detect cancer earlier, today announced the signing of a lease agreement for new office and laboratory space at 1812 Ashland Avenue in Baltimore. PapGene currently operates out of the Stieff Silver Building as part of the Johns Hopkins FastForward incubator program. The company plans to relocate its offices and CLIA-certified laboratory in early 2019 following build out of the new facility.
“We are excited to have identified a new location for PapGene that will accommodate our current and future growth,” said Howard Kaufman, CEO of PapGene. “It was important for us to remain in Baltimore and the growing biotech cluster of talent developing around the Johns Hopkins Medical Center. We are pleased to locate a modern facility with the infrastructure in place for today’s advanced laboratory requirements and a collaborative work environment that will help attract new scientists and professionals to join our mission of detecting cancer earlier to provide opportunity for curative treatment.”